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Abstract
Background: Survival of laryngeal squamous cell carcinoma (LSCC) patients has remained unchanged over recent 
years due to its uncontrolled recurrence and local lymph node metastasis. Vasculogenic mimicry (VM) is an alternative 
type of blood supplement related to more aggressive tumor biology and increased tumor-related mortality. This study 
aimed to investigate the unique role of VM in the progression of LSCC.
Methods: We reviewed clinical pathological data of 203 cases of LSCC both prospectively and retrospectively. VM and 
endothelium-dependent vessel (EDV) were detected by immunohistochemistry and double staining to compare their 
different clinical pathological significance in LSCC. Survival analyses were performed to assess their prognostic 
significance as well.
Results: Both VM and EDV existed in LSCC type of blood supply. VM is related to pTNM stage, lymph node metastasis 
and pathology grade. In contrust, EDV related to location, pTNM stage, T stage and distant metastasis. Univariate 
analysis showed VM, pTNM stage, T classification, nodal status, histopathological grade, tumor size, and radiotherapy to 
be related to overall survival (OS). While, VM, location, tumor size and radiotherapy were found to relate to disease free 
survival (DFS). Multivariate analysis indicated that VM, but not EDV, was an adverse predictor for both OS and DFS.
Conclusions: VM existed in LSCC. It contributed to the progression of LSCC by promoting lymph node metastasis. It is 
an independent predictors of a poor prognosis of LSCC.
Background
Laryngeal squamous call carcinoma (LSCC) is the second
main upper respiratory tract tumor behind lung cancer in
incidence and mortality rates. Despite many advances in
the diagnosis and treatment of the disease, its overall sur-
vival rate has remained unchanged (at approximately 35-
70%) over the past several decades. It is mainly due to
uncontrolled recurrence and local lymph node metasta-
sis[1]. Thus, it is necessary to develope new therapeutic
targets for LSCC that can take advantage of the unique
qualities of this disease.
It is traditionally known that tumor invasion and
metastasis mainly depend on angiogenesis. Histological
examination of human tumor specimens has confirmed
that increased vascularity is a common feature of LSCC.
However, the results of studies associating microvessel
density and various clinical pathological parameters and/
or outcome are still inconclusive in LSCC[2]. In addition,
clinical uses of anti-angiogenic agents for head and neck
squamous cell carcinoma(HNSCC), including bevaci-
zumab, sorafenib, sunitinib, are currently limited to small
clinical trials, and several ongoing large-scaled trials up
to this point. Single-agent anti-angiogenic drugs so far
have not shown activity in unselected HNSCC patients,
with a response rate of less than 4%[3,4].On the other
hand, combinations of anti-angiogenic drugs with other
treatments appear to be promising therapies, and bio-
markers appear to have the potential to play an important
role in anti-angiogenic treatment of LSCC in the future.
Therefore, it is necessary to discover how blood supply
contribute to LSCC biology, and to explore its character-
istic biomarkers.
Vasculogenic mimicry(VM) is an alternative type of
blood supplement formed by highly invasive and geneti-
cally dysregulated tumor cells with a pluripotent embry-
onic-like genotype[5]. Such tumor cells contributes to the
plasticity and gain the ability to participate in the pro-
cesses of neovascularization and ultimately constructing
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a fluid-conducting, matrix-rich meshwork[6]. Tumors
exhibiting in VM related to more aggressive tumor biol-
ogy and increased tumor-related mortality[5]. It has pre-
viously been described in many mesenchymal tumors
such as melanoma[7], synovial sarcoma[8], rhabdomyo-
sarcoma[8], and osteosarcoma[9], and now has spread to
epithelial carcinoma, for example, inflammatory and duc-
tal breast carcinoma [10], ovarian carcinoma[6,11], pros-
tatic carcinoma [12]. We have previousely reported VM
in synoviosarcoma, rhabdomyosarcoma and hepatocellu-
lar carcinoma [13,14]. However, no study exists to our
best knowledge, examining whether VM effects in
squamous cell carcinoma.
In the current study, we detected VM and the tradi-
tional endothelium-dependent vessel (EDV)in 203 cases
of LSCC both prospectively and retrospectively, to com-
pare their different significance on clinical pathology and
prognosis. The results suggested LSCC with VM were
predisposed to develop lymph node metastasis post oper-
ation. VM may be a predictor of lymph node metastasis
for LSCC and poor prognosis instead of EDV. In addition,
we expected that further exploration of specific biomark-
ers of VM will contribute to anti-angiogenesis therapy in
LSCC.
Materials and methods
Patients and Tumor Samples
This study enlisted a total of 203 patients with histo-
pathologically diagnosed LSCC treated at Department of
Head and Neck Surgery of Tianjin Cancer Hospital's from
January 1990 to January 2003. Data collection included
patient gender, age at diagnosis, tobacco use, alcohol con-
sumption, location, tumor size, pTNM stage, T classifica-
tion, lymph node status, distant metastasis, recurrence,
histopathological grade, radiology, and follow-up data.
All of the LSCC patients considered in the study received
the standard surgery protocol according to NCCN Clini-
cal Practice Guidelines in Oncology Head and Neck Can-
cers (2008).All samples were taken by excision, bioptic
specimens were excluded. Follow-up began from post-
operation. The follow up was completed in January 2008.
In the first year of follow-up, the patient had a routine
visit every 2 months (six times a year). In the second year,
the patient is seen every 3 months (four times a year); in
the third year, every 4 months (three times a year); in the
fourth and fifth years, twice a year. Thus all cases
included in this study have been followed for at least 60
months except those patients who died before that time.
The mean follow-up time was 80 months (range 2-219
months). Tumor size was defined as the maximum
dimension of the resected neoplasm. The tumors were
classified according to the TNM and AJCC/UICC sys-
tems (2002). The median age of the patients was 66 years
(range, 32-77 years) at the time of diagnosis, representing
that of the general population with laryngeal cancer. 40 of
203 patients (19.70%) received postoperative radiation
therapy. Tianjin Cancer Hospital's ethics committee
approved the study protocol.
Immunohistochemistry
Main agents
Heat-induced epitope retrieval in citrate buffer (0.01 mol/
L; pH 6.0) was applied to all slides before immunohis-
tochemical staining. The primary antibodies against
CD31 were purchased from Zhongshan Golden Bridge
Biotechnology Co. Ltd., Beijing, PR China. The 0.5% peri-
odic acid and Schiff solutions were made in the pathology
department of Tianjin Cancer Hospital and confirmed to
be effective in previous experiments.
Mono staining
Staining with primary antibodies against CD31 was per-
formed on formalin-fixed, paraffin-embedded tissues
with the SP-9000 kit (Zhongshan Golden Bridge Biotech-
nology Co. Ltd., Beijing, PR China).
Double Staining
First, CD31 immunohistochemical staining was applied;
then the sections were treated with 0.5% periodic acid
solution for ten minutes and rinsed with distilled water
for two-three minutes. In a dark chamber, these sections
were treated with Schiff solution for fifteen-thirty min-
utes. After distilled water rinsing, sections were counter-
stained with hematoxylin.
Evaluation of the Staining
VM was first identified with hematoxylin-eosin staining
slides. It could be seen to be formed by tumor cells but
not endothelial cells without hemorrhage, necrosis, or
inflammatory cells infiltrating near these structures.
CD31/periodic acid-Schiff (PAS) double-stained was
then used to validate VM. It was identified by the detec-
tion of PAS-positive loops surrounding with tumor cells
(not endothelial cells), with or without red blood cells in
it. In CD31-stained slides, there were no positive cells in
VM. Microvessel density (MVD) was determined by light
microscopy examination of CD31-stained sections at the
"hot spot". The fields of greatest neovascularization were
identified by scanning tumor sections at low power
(×100). The average vessel count of three fields (×400)
with the greatest neovascularization was regarded as the
MVD. The MVD was classified as either high (≥17.53) or
low (<17.53); 17.53 was the median value of MVD.
Statistical Analysis
Analyses were conducted in the SPSS software version
11.0 (SPSS, Inc., Chicago, IL). The Kruskal-Wallis Test
was used to compare the positive rate of VM with clinical
pathologic variables, as appropriate, while using One-
Way ANOVA to analyze the relationship with clinical
pathologic data. Overall and disease-free survival curvesWang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:60
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were plotted using the Kaplan-Meier method and differ-
ent subgroups were compared using the log-rank test.
Patients who dropped out during follow-up or died due
to diseases other than laryngeal cancer were treated as
censored cases. The Cox regression model was used to
adjust for potential confounders. Comparison MVD
expression between VM-positive and VM-negative group
used t test. Significant level was set at 0.05. P values are
two-tailed.
Results
Evidence of VM and EDV in LSCC
Both VM and EDV existed in LSCC. Forty-four (21.67%)
of 203 cases were VM-positive by double-staining. VM
appeared to be PAS-positive loops surrounding tumor
cells (not endothelial cells), with or without red blood
cells. In CD31-stained slides, there were no positive cells
in VM (Fig. 1A). While endothelium dependent vessel
showed a CD31-positive endothelial cell to form the ves-
sel wall (Fig. 1B).
Characteristics and follow up of patients
Among the 203 patients, there were 154 men (75.86%)
and 49 women (24.14%). The mean age at diagnosis was
66 years, ranging from 32 to 77 years. 166 (81.77%) cases
reported history of tobacco use, and 37 (18.23%) cases
without. 91 (44.83%) cases indicated history of alcohol
consumption and 112 (55.17%) cases without. Patients
with tumors located at super glottic were 93 (45.81%)
cases, at glottic were 93 (45.81%) cases, and at subglottic
were 17 (8.37%) cases. Patients in pTNM stage I, II, III
and IV were 25 (12.32%), 60 (29.56%), 62 (30.54%) and 56
(27.59%), respectively. Patients in different T classifica-
tion T1, T2, T3 and T4 were 27 (13.30%), 93(45.81%),
44(21.67%) and 39(19.21%), respectively.151(74.38%)
patients showed lymph node metastasis at diagnosis, and
19 (9.36%) patients appeared to show distant metastasis
postoperative. In addition, histological grade 1 was in 30
(14.78%), grade 2 was in 149 (73.40%) and grade 3 was in
24 (11.82%) cases.
The mean follow-up time was 80 months (range 2-219
months). 121 patients (59.61%) were alive when the fol-
low up ended. Eighty-two patients (40.39%) died as a
result of their malignancy. The median DFS was 56
months. Local recurrence and local lymph node metasta-
sis was observed in 157 patients (77.34%). The mean
period from initial surgery to the first local recurrence or
metastasis was 63.71 months (range 1-213 months).
Nineteen (9.36%) patients developed distant metastasis.
The metastatic sites included lung (n = 9), bone (n = 4),
liver (n = 3), mediastinum (n = 2), and multiple concomi-
tant metastasis (n = 1, including thoracic vertebrae, spinal
cord and tibia).
Clinical significance of VM in LSCC patients compared with 
EDV
Clinical significance of VM and EDV are listed in Table 1.
The positive rate of VM was significantly higher in pro-
gressive stage (III and IV) than primary stage (I and II)
(27.97% vs. 12.94%) (p = 0.010) clinically, and it was sig-
nificantly greater in patients with local lymph node
metastases than those without local lymph node metasta-
sis (36.53% vs. 16.56%) (p = 0.003). In addition, the posi-
t i v e  r a t e  o f  V M  b e c a m e  h i g h e r  w i t h  t h e  r a i s e  o f
Figure 1 Identifying VM and EDV in human sample of LSCC by CD31and PAS double staining. A.) The VM channel (black arrow) in human sam-
ple is formed by laryngeal cancer cells. There are red blood cells in the center of the channel. PAS-positive substances line the channel and form a 
basement membrane-like structure (pink). Note the absence of necrosis and hemorrhage in the tumor tissue near the VM channel (original magnifi-
cation: ×400). B.) Endothelium-dependent vessels (black arrows) are lined by spindle-shape endothelial cells, which are stained by CD31 (brown). The 
vessels' basement membrane is positive for PAS staining (pink) (original magnification: ×400).Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:60
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Table 1: Comparing clinicalpathologic significance of VM and EDV
factor VM MVD
+- χ2 P
( ±  S )
F/t* P
Gender 0.881 0.380 1.228* 0.269
M 34 118 17.8739 ± 6.82709
F 10 42 16.6340 ± 6.08995
Age 0.370 0.712 0.108* 0.742
≥60 22 85 17.4393 ± 6.92216
<60 22 74 17.7514 ± 6.57988
Tobacco use
Yes 37 129 0.202 0.653 17.3863 ± 6.67757 0.808* 0.370
No 7 30 18.4865 ± 6.97671
Alcohol consumption 0.608 0.436 0.008* 0.927
Yes 22 69 17.5388 ± 6.43099
No 22 90 17.6259 ± 6.99013
Location 2.213 0.331 3.550 0.031
Super glottic 24 69 18.2441 ± 7.14615
glottic 18 75 16.3786 ± 5.94319
subglottic 2 15 20.3667 ± 7.35727
pTNM 6.570 0.010 7.419* 0.007
I+II 11 74 16.0306 ± 6.19107
III+IV 33 85 18.5977 ± 6.91980
Tumor size (cm) 0.220 0.639 0.974* 0.325
≥3 20 66 18.1306 ± 6.22807
>3 24 93 17.1872 ± 7.07416
T stage 1.278 0.734 3.396 0.019
T1 6 21 13.8593 ± 5.61853
T2 17 76 17.7731 ± 6.43417
T3 11 33 17.9143 ± 6.69789
T4 10 29 18.8667 ± 7.50099
Nodal status 9.097 0.003 0.019* 0.892
N-positive (N1, N2, N3) 19 33 17.4769 ± 6.50208
N-negative(N0) 25 126 17.6247 ± 6.82606
Distant metastasis 1.535 0.215 4.077* 0.045
Yes 2 17 20.4684 ± 6.86740
No 42 142 17.2186 ± 6.65992
Recurrence 0.005 0.994 0.679* 0.498
Yes 7 26 18.3152 ± 6.59413
No 37 133 17.4455 ± 6.76481
Histopathological grade 15.531 0.000 0.209 0.811
1 2 28 16.8967 ± 5.69443
2 30 119 17.7532 ± 7.12289
3 12 12 17.4167 ± 5.42896
VM: vasculogenic mimicry; EDV: endothelial dependent vessel; LSCC: laryngeal squamous cell carcinoma; TNM: tumor, node, metastasis.
xWang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:60
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histopathological grade: grade 1(6.67%), grade 2 (20.13%),
grade 3 (50.00%) (p < 0.0001). And the incidence of VM
did not differ with respect to the patients' gender, age,
tumor size, T stage, tumor location, recurrence or distant
metastasis (all P > 0.05).
We performed immunohistochemical staining for
CD31, a classic endothelial cell marker, to label endothe-
lial dependent vessel, and analyzed whether it was associ-
ated with tumor clinicopathologic characteristic. The
results showed MVD was correlated to location (p  =
0.031), pTNM stage (p = 0.007), T stage (p = 0.019) and
distant metastasis (p = 0.045). While, showed no associa-
tion between MVD and gender, age, tobacco use, alcohol
consumption, tumor size, lymph node metastasis, recur-
rence or histopathological grade (all P > 0.05).
Survival analysis
Univariate analysis showed that survival of VM-positive
patients was significantly poorer than that of VM-nega-
tive patients in OS (p = 0.014) (Fig. 2A). Furthermore,
pTNM stage (P  = 0.009), T classification (P  = 0.013),
nodal status (P = 0.013), and histopathological grade (P =
0.038), tumor size (P = 0.028), radiotherapy (P < 0.0001)
correlated with OS. However, there was no significant
association between OS and gender, age at diagnosis,
tobacco use, alcohol consumption, location, distant
metastasis, recurrence and MVD (Fig. 2B) (all P > 0.05;
Table 2). Multivariate analysis indicated that the presence
of VM (risk ratio (RR) = -2.117, P = 0.003), recurrence
(RR = -1.821, P = 0.020) and pTNM stage (RR = 1.367, P =
0.009) were adverse predictors for OS (Table 3), while
radiotherapy were indicators of a good prognosis of OS
(RR = 2.872, P < 0.0001).
In addition, univariate analysis of DFS showed that VM
(P = 0.011) (Fig. 2C), location (P = 0.049), tumor size (P =
10.364) and radiotherapy (P <0.0001) were proposed to
correlate with DFS. While, gender, age at diagnosis,
tobacco use, alcohol consumption, pTNM stage, T classi-
fication, nodal status, distant metastasis, recurrence, his-
topathological grade and MVD (Fig. 2D) (all P > 0.05;
Table 2) showed no correlation with DFS. Multivariate
analysis showed that VM (RR = -1.733, P = 0.003) and
radiotherapy (RR = 2.756, P < 0.0001) were independent
prognostic factors for DFS (Table 3).
Relationship between VM and EDV
To elucidate on the relationship between VM and EDV,
the MVD between the VM-positive group and VM-nega-
tive group was compared. This determined patients of
VM-negative group had a higher MVD (18.3403 ±
6.92318) than the VM-positive group (14.8643 ± 5.18685)
(t = 3.096, p  = 0.002) (Table 4). Correlation analysis
revealed a negative correlation between VM and MVD (r
= -0.198, p = 0.005).
Discussion
This study confirmed VM as a new type of blood supply
in LSCC by double staining. Angiogenesis (the formation
or sprouting of endothelium-lined vessels from pre-exist-
ing vessels) and vasculogenesis (the difference between
precursor cells and endothelial cells which develop de
novo  vascular networks) are two kinds of traditional
blood types [15]. Both have been reported in LSCC[16].
VM is a new pattern of matrix-rich networks surrounding
tumors cells, being reported firstly in melanoma by Man-
iotis in 1999 [5]. It refers to the de novo generation of
tumor microcirculation without participation by
endothelial cells; it is independent of angiogenesis. Fur-
thermore, it is not a vasculogenic event for the true vas-
culogenesis results in endothelial cell-lined vessels' de
novo formation. Majority of research on VM focuses on
mesenchymal tumor [8,9,17], while only a few delve into
epithelial tumor [6,10,11,18]. To date, there is dearth of
research discussing squamous cell carcinoma. Thus, this
study identifies VM existence in LSCC, in attempt to
explain why anti-angio/vaculogenesis treatment remains
to be clinically ineffective.
There is still no affirmative conclusion on the prognos-
tic significance of the endothelium marker among CD31,
CD34 and CD105. A long-term prognostic significance of
angiogenesis in breast carcinomas compare with Tie-2/
Tek, CD105, and CD31 immunocytochemical expression
showed both CD31 and CD105 correlated with poorer
survival [19]. Menio et al study on lung cancer reported
that CD34-MVD and tumor vessel invasion not CD105,
correlate with poor survival on multivariate analysis[20].
We selected CD31 to label endothelial-dependent vessel
for the reasons: Because CD31/CD34 is a pan endothelial
marker, and hence stains nearly all blood vessels, both
stable vessels trapped inside the tumor and neoangiogen-
esis. However, CD105 (endoglin) is a proliferation-associ-
ated and hypoxia-inducible protein abundantly expressed
in angiogenic endothelial cells. It is demonstrated that
antibodies against CD105 reacted preferentially with
active endothelial cells of angiogenic tissues. CD105 is a
marker of neoangiogenesis and only stains a smaller pro-
portion of blood vessels[21]. On the other hand, VM is an
alternative type of blood supplement different from
endothelium-lined vasculature. It is becoming evident
that VM, the intratumoral, tumor-cell-lined, ECM-rich,
patterned network, can provide an extra vascular fluid
pathway, now known as the fluid-conducting mesh-
work[22,23]. Here, we compared clinical significance of
VM with CD31-MVD, to disclose their different contri-
bution to tumor biology. Thus, we choose CD31 to label
endothelial-dependent vessel rather than CD105 was in
order to reflect the whole blood supply in a tumor, for
both newly-forming vessels and stable vessels trapped
inside the tumor acted in tumor invasion and metastasis.Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:60
http://www.jeccr.com/content/29/1/60
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More work should be done in the future to enrich the the-
ory of tumor blood supply pattern, which may provide
reasonable theoretic evidence for tumor anti-angiogene-
sis.
In the current study, we identified that the positive rate
of VM in LSCC is 21.67%, which is different from other
tumors, such as inflammatory and ductal breast carci-
noma (7.9%), ovarian carcinoma(36.4%), mela-
noma(5.3%), rhabdomyosarcoma(18.8%), and synovial
sarcoma(13.6%). That is probably due to different tissue
origin and judgment criteria variable across labs. More
investigation of a larger sample is needed to illustrate the
mechanism of VM formation in different tissue.
Previous research has demonstrated VM existed in
most tumors, being a functional microcirculation [24,25],
correlated with poor clinical outcomes among tumor
patients [14,26]. The majority of studies in vitro have
focused on the mechanism, until recently. However, rela-
Figure 2 The curves of overall survival and disease-free survival according to VM and MVD in 203 patients with LSCC. A.) Overall survival ac-
cording to VM positive and VM negative (p = 0.014). B.) Overall survival according to high MVD (MVD≥17.53) and low MVD (MVD?17.53) (p = 0.772). 
17.53 was the average MVD of 203 cases of LSCC patients. C.) Disease-free survival according to VM positive and VM negative (p = 0.011). D.) Disease-
free survival according to high MVD and low MVD (p = 0.847).Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:60
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tively few studies have interpreted VM's influence on a
tumor's overall biological behavior using a large sample.
In addition, there still no data which describes a signifi-
cant difference between VM and other patterns of blood
s u p p l y .  I n  t h i s  s t u d y ,  w e  c o m p a r e d  t h e  s i g n i f i c a n c e  o f
clinicopathology and prognosis between VM and EDV.
This retrospective study of 203 LSCC patients showed
that VM is associated with lymph node metastasis,
pTNM stage and histopathology grade in LSCC. While
EDV correlated with tumor location, pTNM stage, T
stage and distant metastasis. This indicated that both VM
and EDV played an important role in tumor progression.
Our study showed that VM is related to local lymph
node metastasis intimately, which is an important feature
and a key prognostic factor of LSCC[27]. It is different
from a previous study[28], which reported that patients
with breast carcinomas engaged in VM and had a higher
rate of distant metastasis (liver, lung, and bone), but failed
to find a significant correlation with lymph node metasta-
sis status. In our study of 203 LSCC, only 9.36% appeared
to have distant metastasis, while 74.38% developed local
lymph node metastasis. We deduced from this that VM
in LSCC may own the specific ability to facilitate metas-
tasis by some modality. More studies are warranted to
elucidate the effects of VM which use a larger sample on
local lymph node metastasis in different types of tumors.
VM in tumors plays an important role in tumor aggres-
s i o n  [ 5 ] .  W e  a l s o  f o u n d  V M  i s  m o r e  c o m m o n  i n  t h e
advanced stage of LSCC than in the primary stage. How-
ever, these results are different than the observations
from a breast cancer study by Shirakawa et al[28], which
showed that the VM group did not exhibit a more
advanced pTNM stage than the non-VM group. However,
there was no difference of VM exhibition among different
T stage founded in Shirakawa's and our studies. We sug-
gested that the discrepancy result may due to different
influence of VM on local lymph node metastasis or dis-
tant metastasis in diversity tumors. Therefore, the impact
of VM on the survival of patients with LSCC needs to be
confirmed further by some international collaboration of
studies and systematic reviews by meta-analysis.
In addition, we founded that positive rate of VM
increased with the increase of histopathology grade,
which is consistent with a previous study of hepatocellu-
lar carcinoma [14]. Nasu et al's [29]in vitro study demon-
strated that VM was linked to the aggressive tumor cell
phenotype. Another in vitro study [6] also found that high
invasive melanoma cell line MUM-2B, expressing both
epithelial and mesenchymal phenotype was able to form
VM, while MUM-2C, a low invasive melanoma cell line
expressing only mesenchymal phenotype, failed to form
VM. Taken together, these studies imply that the lower
Table 2: Univariate analyses of factors associated with recurrence, metastasis and survival
Variable Overall 
Survival
Disease-Free
Survival
χ2 P χ2 P
Sex, male vs female 1.809 0.179 0.690 0.496
Age, y, ≥60 vs <60 0.075 0.784 0.342 0.559
Tobacco, Yes vs No 2.371 0.124 2.661 0.103
Drink, Yes vs No 0.013 0.911 0.648 0.421
Location, Super glottic vs glottic vs subglottic 0.585 0.746 6.035 0.049
pTNM stage, Ivs II vs III vs IV 11.600 0.009 4.592 0.204
T classification, T1 vs T2 vs T3 vs T4 10.744 0.013 6.915 0.075
Nodal status, N-positive vs N-negative 6.238 0.013 0.583 0.445
Distant Metastasis, Yes vs No 0.042 0.837 0.374 0.541
Recurrence, Yes vs No 12.386 <0.0001 0.043 0.836
Histopathological grade, 1 vs 2 vs 3 6.529 0.038 1.274 0.529
Tumor size, cm, ≥3 vs <3 4.809 0.028 10.364 0.001
Surgery modality
(cervical neck dissection) Yes vs No
0.672 0.412 1.122 0.290
Radiotherapy, Yes vs No 26.752 <0.0001 27.750 <0.0001
MVD, <17.53 vs ≥17.53 0.084 0.772 0.037 0.847
VM, Yes vs No 6.054 0.014 6.535 0.011
VM: vasculogenic mimicry; MVD: micro vessel density.Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:60
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histopathology grade of LSCC owning more cell hetero-
morphism, can change cancer plasticity by genetic rever-
sion to a pluripotent embryonic-like genotype to
ultimately form VM. However, in the study of EDV, it was
both VM and EDV were related to pTNM, while no asso-
ciation was found between EDV and pTNM rather than
distant metastasis. Therefore, we speculated that both
VM and EDV contributed to LSCC progression, but
through a diverse pathway. VM is a distinct pattern of
blood supply from EDV . In general, VM ma y facilita te
invasion and local metastasis in LSCC, indicating its role
on aggressive behavior.
Previous study demonstrated that tumors with VM
exhibited poor survival[9,13]. We found that VM was an
unfavorable prognostic factor of LSCC patients both in
OS and DFS, whereas EDV was not an independent pre-
dictor of outcome, consistent with Sun et al's [14] investi-
gation in hepatocellular carcinoma. Traditional
microvessel density counts [30,31] within vascular hot
spots of tumors using endothelial markers reflect only the
vascular status of endothelial dependent vessel in a
tumor, but ignore other patterns of the vascularity,
including VM, leading to low microvessel density in the
different tumor types. However, Eberhard et al[32] dem-
onstrated that endothelial dependent vessel alone, there
is wide variance in the endothelial proliferation index
among the various tumor types. This indicated that there
is marked heterogeneity of vasculature in human tumors.
It is necessary for us to account for all types of blood sup-
ply and their contribution to tumor behavior when evalu-
ating its clinical and prognostic value. Moreover, the
phenomenon of VM existence can partly explain why we
failed in anti-angiogenesis treatment of LSCC.
How do VM and EDV play their individual role in one
neoplasm during tumor growth? In our retrospective of
203 cases LSCC, presentation of VM showed a negative
correlation with EDV. Further investigation in vivo needs
to be performed in order to detect the presence of VM
and EDV to disclose the relationship between VM and
EDV in the same tumor in a time-dependent way.
Conclusions
In conclusions, our results suggest that VM might be a
new target of anti- vasculogenesis/angiogenesis therapy
for LSCC. Those who rely on conventional markers of
tumor "vascularity" as prognostic markers, and who are
developing anti-cancer therapies by targeting angiogene-
sis should exercise caution concerning VM when inter-
preting their results. Vasculogenic mimicry is one
example of the remarkable plasticity demonstrated by
aggressive melanoma cells and suggests that these cells
have acquired an embryonic-like phenotype. Several fac-
tors are involved in VM formation, including microenvi-
ronment, interaction between tumor cells and
surrounding tissue, tumor cells changing to endothelial
genotype by expressing embryo genotype. Further studies
Table 3: Multivariate analyses of factors associated with recurrence, metastasis and survival
Variable Hazard Ratio 95% Confidence Intervals p
lower upper
Overall Survival VM, Positive vs Negative -2.117 1.286 3.425 0.003
Recurrence, Yes vs No -1.821 1.363 3.639 0.020
TNM stage, Ivs IIvs IIIvs IV 1.367 1.080 1.732 0.009
Radiotherapy, Yes vs No 2.872 1.764 4.678 <0.0001
Disease-free 
Survival
VM, Positive vs Negative -1.733 1.202 2.498 0.003
Radiotherapy, Yes vs No 2.756 1.893 4.012 <0.0001
VM: vasculogenic mimicry; MVD: micro vessel density.
Table 4: Correlation between VM and MVD of 203 LSCC patients
n
MVD (  ± S)
tP
VM+ 44 14.8643 ± 5.18685 3.096 0.002
VM- 159 18.3403 ± 6.92318
VM: vasculogenic mimicry; MVD: micro vessel density.
xWang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:60
http://www.jeccr.com/content/29/1/60
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are needed to elucidate the specific molecular mecha-
nism of VM in LSCC on order to explore new therapies
target, and to contribute to anti-vasculogenesis/angio-
genesis therapy for vasculogenic mimicry in LSCC.
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